Results 1 to 10 of about 36,481 (278)

The Clinical Significance of CD73 in Cancer

open access: yesInternational Journal of Molecular Sciences, 2023
The search for new and effective treatment targets for cancer immunotherapy is an ongoing challenge. Alongside the more established inhibitory immune checkpoints, a novel potential target is CD73. As one of the key enzymes in the purinergic signalling pathway CD73 is responsible for the generation of immune suppressive adenosine. The expression of CD73
Riekje Winzer   +2 more
exaly   +4 more sources

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73- Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes [PDF]

open access: yesCells, 2020
The ectonucleotidases CD39 and CD73 regulate immune responses by balancing extracellular ATP and adenosine in inflammation and are likely to be involved in the pathophysiology of COVID-19. Here, we analyzed CD39 and CD73 on different lymphocyte populations in a small cohort of COVID-19 patients and in healthy individuals.
Philip Hartjen   +2 more
exaly   +5 more sources

CD73 Activity is Dispensable for the Polarization of M2 Macrophages.

open access: yesPLoS ONE, 2015
The ectoenzyme CD73 catalyzes the hydrolysis of AMP, and is one of the most important producers of extracellular adenosine. On regulatory T cells, CD73 is necessary for immunosuppressive functions, and on Th17 cells CD73-generated adenosine exerts anti ...
Dominik Eichin   +3 more
doaj   +6 more sources

Targeting CD73 in the tumor microenvironment with MEDI9447 [PDF]

open access: yesOncoImmunology, 2016
MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences.
Raymond Rothstein   +2 more
exaly   +3 more sources

Cd73: An Emerging Checkpoint for Cancer Immunotherapy [PDF]

open access: yesImmunotherapy, 2019
CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of ...
Siqi Chen   +2 more
exaly   +3 more sources

CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism

open access: yesAdvanced Science, 2023
CD73, a cell surface‐bound nucleotidase, facilitates extracellular adenosine formation by hydrolyzing 5′‐AMP to adenosine. Several studies have shown that CD73 plays an essential role in immune escape, cell proliferation and tumor angiogenesis, making it
Xiaozhou Yu   +2 more
exaly   +2 more sources

CD73 overexpression in ADSCs accelerates bladder repair by regulating the NFκB/NLRP3/caspase-1 signaling axis in neurogenic bladder rats [PDF]

open access: yesnpj Regenerative Medicine
Neurogenic bladder (NB) is a disabling condition lacking effective therapies. This study investigated whether CD73-expressing adipose-derived stem cells (ADSCs) promote bladder repair in a rat model of NB and explored the underlying mechanisms.
Guanqun Zhu   +10 more
doaj   +2 more sources

CD73 blockade alleviates collagen-induced arthritis by inhibiting synovial fibroblast activity [PDF]

open access: yesIranian Journal of Basic Medical Sciences
Objective(s): Rheumatoid arthritis (RA) is a chronic autoimmune disease with progressive cartilage erosion and joint destruction. CD73 plays a critical role in regulating inflammatory responses. This study aims to investigate the effects of CD73 blockade
Xia-nan Wu   +6 more
doaj   +2 more sources

Blockade of CD73 Increases the Cytotoxic Effects of Fludarabine in Chronic Lymphocytic Leukemia [PDF]

open access: yesImmunoAnalysis, 2022
Background: Ecto-5’-nucleotidase (CD73) is a membrane-bound enzyme that converts adenosine 5’-monophosphate into adenosine. It is proven that the presence of elevated levels of adenosine in the tumor microenvironment induces tumor growth while ...
Mohammad Sadeghi   +5 more
doaj   +1 more source

Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML

open access: yesOncoImmunology, 2021
The inhibitory receptor TIGIT, as well as theectonucleotidases CD39 and CD73 constitute potential exhaustion markers for T cells. Detailed analysis of these markers can shed light into dysregulation of the T-cell response in acute myeloid leukemia (AML ...
F. Brauneck   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy